作者: William E. Hurford , Wolfgang Steudel , Warren M. Zapol
DOI: 10.1007/978-1-4612-1326-0_10
关键词: Pulmonary hypertension 、 Internal medicine 、 Pulmonary artery 、 Acute respiratory failure 、 Nitric oxide 、 Prostaglandin 、 ARDS 、 Medicine 、 Cardiology 、 Vasodilation 、 Prostacyclin
摘要: Pulmonary hypertension and severe hypoxemia complicate the care of patients with diseases such as acute respiratory distress syndrome (ARDS). Numerous vasodilator therapies aimed at reducing pulmonary have been tested in these patients. All currently available intravenous vasodilators produce systemic vasodilation hypotension dosages sufficient to reduce artery pressure. In addition, infusions nitroprusside or prostacyclin (prostaglandin I2; PGI2) markedly increase venous admixture (Radermacher et al. 1990). 1991, inhaled nitric oxide (NO) was reported selectively vasodilate circulation (Fratacci 1991; Frostell 1991). The use this novel therapy an adjunct treatment ARDS has attracted immense interest.